FDA MEMORANDUM CIRCULAR

No. 2013-029

TO: All FDA Regular and Contractual Employees, and Other Concerned Parties

SUBJECT: FAIR AND EQUAL TREATMENT TO ALL FDA CLIENTS, CONSUMERS AND OTHER STAKEHOLDERS

The Office of the Director General and the Center Directors have received reports from recently hired Food and Drug Administration (FDA) regular and contractual employees that there were incidents of some company liaison officers and regulatory affairs officers who have been dropping names of former FDA employees, who already resigned or retired from government service, in an effort to get special treatment or accommodation.

Electronic submissions of regulatory requirements and automation of work processes in the different FDA Centers and Offices are part of the on-going reforms that will ensure fair and equal treatment of all clients, consumers and other stakeholders. The reforms being implemented are in line and consistent with Republic Act No. 9485, otherwise known as the Anti-Red Tape Act of 2007 (ARTA). The ARTA Laws was passed in response to the urgent need to improve efficiency of delivering government frontline services and to establish an effective system that will eliminate bureaucratic red tape, avert graft and corrupt practices.

All FDA employees are hereby ordered to directly report to the Office of the Director General or the Deputy Director General for Administration and Finance any incident of name-dropping or complaint of harassment from company liaison officers or regulatory affairs officers in order to gain favor, undue advantage over others, or suggests special treatment or accommodation.

Kenneth Y. Hartigan-Go, MD
Acting Director General